Currently, a Phase II clinical trial is evaluating the IL‐6 antibody (tocilizumab) combined with chemotherapy for pancreatic cancer, aiming to improve treatment response and alleviate cachexia [702]. This evidence concerns the gene IL6 and pancreatic neoplasm.